Physician profile
Kelli Meeks
NPI 1255172870
$2,067.11
in general payments reported to CMS, 2019-2025
18 companies · $2,067 in 2025
The $2,067 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $383.09 | 2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $345.81 | 2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $278.13 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $206.66 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.70 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $106.35 | 2025 | |
| Astellas Pharma US INC | $99.21 | 2025 | Veozah |
| Lilly USA, LLC | $85.92 | 2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.31 | 2025 | Caplyta |
| Paratek Pharmaceuticals, INC. | $57.93 | 2025 | Nuzyra, Xhance |
| Amgen INC. | $56.83 | 2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $54.36 | 2025 | Verquvo |
| Pfizer INC. | $46.65 | 2025 | |
| Novartis Pharmaceuticals Corporation | $34.78 | 2025 | |
| Alkermes, INC. | $28.44 | 2025 | Lybalvi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.69 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.53 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $15.72 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Meeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.